Dr. Andrew Napper studied at the University of Oxford and Penn State University before working in the Boston area for Genzyme, Enanta, ArQule, and Elixir Pharmaceuticals. While at Elixir, he played a leading role in the discovery of selisistat (EX-527), which was licensed to Siena Biotech and progressed to Phase II clinical trials as a treatment for Huntington’s disease. In 2005, he joined the University of Pennsylvania to direct one of the labs in the Molecular Libraries Screening Center Network. Dr. Napper joined Nemours in 2009 to establish a lab focused on the discovery of targeted therapies for rare pediatric diseases. He is Chair of the Academic Drug Discovery Special Interest Group for the Society for Lab Automation and Screening, Deputy Editor of the journal Assay and Drug Development Technologies, a Review Editor for Frontiers in Pediatric Oncology, and an Enzyme Assays Editor for the Assay Guidance Manual.
Monday, January 27
2:30 PM – 3:45 PM